BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Mucosis B.V. Appoints Thomas Johnston As Chief Business Officer


5/17/2011 10:26:36 AM

Groningen, the Netherlands, May 17, 2011 / B3C newswire / - Dutch biotechnology company Mucosis B.V. today announced the appointment of Thomas Johnston as Chief Business Officer. In this role he will have global responsibility for the licensing and marketing of Mucosis’s technologies, negotiating corporate partnerships and other strategic alliances. Mr. Johnston joins Mucosis from Novavax Inc, a Nasdaq-listed clinical-stage biopharmaceutical company. As Vice President of Strategy he developed and executed a regional partnership strategy with deals in India, Mexico, and South Korea. Prior to Novavax, Mr. Johnston served as an executive-level strategic consultant in a number of industries including biotech, and held various senior-level positions with a number of world-class organizations such as Comcast, Microsoft, and Schlumberger. Mr. Johnston holds an M.B.A. from The Wharton Business School and a Bachelor of Science degree in Computer Science from Arcadia University.

“Tom has more than 15 years of business development experience and an in-depth understanding of the vaccine and biotechnology space. Therefore we are very pleased to welcome him to our team” said Govert Schouten, Chief Executive Officer of Mucosis. “Through this appointment, we extend our business development reach for the success of our Mimopath™-based vaccine candidates."

Tom Johnston added: “I am excited to join the Mucosis management team. The company has made great progress to date and is now ready to move to broadening market awareness of its technology platform and vaccine pipeline.”

About Mucosis

Mucosis B.V. is a Dutch biotechnology company with a proprietary platform technology, Mimopath™ , on which it develops mucosal vaccines with improved efficacy. Mucosis’s lead products are FluGEM™, a vaccine to prevent influenza; PneuGEM™, a vaccine to prevent diseases caused by pneumococcal bacteria; and SynGEM™, a vaccine to prevent RSV viral infection. Mimopath™ -based vaccines can be administered needle-free in the nose and mouth, evoking a more natural immune response with a broader base of protection.

About Mimopath™ technology

The Mimopath™ technology is based on Lactococcus lactis, a safe bacterium commonly used in the food industry. Mucosis has developed a robust technique to formulate the L. lactis bacteria into non-living bacterium-like particles (BLPs) that can be loaded with antigens from viral, bacterial, parasitic or tumor origin. The antigen-covered BLPs form a vaccine that can be delivered into the nose or mouth, without the need for a needle. These vaccines raise protective immunity by activation of both the innate and the adaptive immune system.

Contact

Govert Schouten

CEO Mucosis

+31 (6) 55320948

govert.schouten@mucosis.com

www.mucosis.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES